Keith T Flaherty
ECOG-ACRIN Cancer Research Group · Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Keith T Flaherty as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02465060 · Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma · principal investigator
- Ph2NCT00717587 · Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney CancerAbramson Cancer Center at Penn Medicine · unknown · Kidney Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT02465060
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT02465060
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:00 UTC. The ranking covers the 200 most relevant of 115 PubMed records, and a shared surname and initials can bring in a namesake. All 115 on PubMed
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med · 20116,168 citationsRCR 158.5
- Inhibition of mutated, activated BRAF in metastatic melanoma.N Engl J Med · 20102,851 citationsRCR 65.3
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med · 20122,244 citationsRCR 58.2
- Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med · 20122,097 citationsRCR 54.1
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med · 20121,765 citationsRCR 46.2
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Nature · 20101,437 citationsRCR 31.5
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.N Engl J Med · 20191,120 citationsRCR 41.8
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.N Engl J Med · 2012873 citationsRCR 21.8
- Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.J Clin Oncol · 2006823 citationsRCR 18.4
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol · 2018820 citationsRCR 27.7